The FDA's alignment on an accelerated approval pathway for AMT-130 is a transformative catalyst that likely overrides the headline earnings miss. Traders should focus on the BLA submission timeline and the four-year data readout in September 2026 as the next key catalysts. The $259M capital raise removes near-term financing risk and funds the commercial launch, but adds dilution.
Price Chart
Executive Summary
uniQure reported Q2 2026 results with a net loss of $1.22 per share, significantly missing the $-0.71 consensus estimate, while revenue of $5.8M slightly beat the $4.7M estimate. The headline miss is overshadowed by a transformative regulatory milestone: FDA alignment on an accelerated approval pathway for AMT-130 in Huntington's disease, with a BLA submission on track for Q3 2026. The company also strengthened its balance sheet with a $259M follow-on offering, extending the cash runway into 2030 and funding a potential commercial launch.
Key Financial Metrics
Key Facts
- FDA and uniQure reached alignment that a BLA submission under the accelerated approval pathway for AMT-130 is reasonable.
- BLA submission for AMT-130 on track for Q3 2026; topline four-year data expected in September 2026.
- Closed an upsized underwritten public offering of 5,686,813 shares at $45.50 per share for aggregate gross proceeds of $259 million.
- Cash, cash equivalents and current investment securities of $810.3 million as of June 30, 2026, sufficient to fund operations into 2030.
- Net loss of $81.1 million ($1.22 per share) for Q2 2026, compared to a net loss of $37.7 million ($0.69 per share) in Q2 2025.
- Revenue for Q2 2026 was $5.8 million, up from $5.3 million in Q2 2025.
Financial Impact
EPS miss of -72.4% vs consensus ($-1.22 actual vs $-0.71 estimate). Revenue beat of +23.4% vs consensus ($5.8M actual vs $4.7M estimate). Net loss widened to $81.1M from $37.7M YoY, driven by $27.0M in non-operating expenses (FX and warrant revaluation).
Risk Factors
- FDA may ultimately conclude that Phase I/II data are insufficient to support a BLA or accelerated approval.
- Confirmatory study design and enrollment timeline remain to be finalized with the FDA.
- Net loss widened significantly YoY due to non-operating items; operating expenses continue to rise.
- Dilution from the 5.7M share follow-on offering at $45.50 per share.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-087808 |
| Document: qure-20260729x8k.htm | 0001104659-26-087808 |
| Document: 0001104659-26-087808-index-headers.html | 0001104659-26-087808 |
| Document: 0001104659-26-087808-index.html | 0001104659-26-087808 |
| Document: 0001104659-26-087808.txt | 0001104659-26-087808 |
| 8-K Data (Synthetic) | 0001104659-26-087808 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $46.23 $44.47 | ▼ −3.81% | ▼ −2.85% | $23.46 (−49.25%) |
Jul 29, 2026 9w ago | 8-K | $40.07 $44.24 | ▲ +10.41% | ▲ +4.88% | $23.46 (−41.45%) |
Jul 7, 2026 12w ago | Insider Cluster | $41.41 $41.52 | ▼ −0.27% | ▲ +0.29% | $23.46 (+43.35%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▼ −6.39% | ▼ −5.46% | $23.46 (+43.89%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jul 2, 2026 13w ago | 144 | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jun 30, 2026 13w ago | 144 | $45.17 $41.41 | ▼ −8.32% | ▼ −8.59% | $23.46 (−48.06%) |
Jun 25, 2026 14w ago | 144 | $47.51 $41.81 | ▲ +12.00% | ▲ +14.16% | $23.46 (+50.62%) |
Jun 24, 2026 14w ago | 424B5 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
Jun 24, 2026 14w ago | 144 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access